Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager

Ascendis Pharma A/S

NASDAQ:ASND

Watchlist

Dividends

Price: 129.81 USD 5.85% Market Closed

Market Cap: 7.4B USD

Have any thoughts about
Ascendis Pharma A/S?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US		Fubotv Inc NYSE:FUBO	Media
US		Bank of America Corp NYSE:BAC	Banking
US		Palantir Technologies Inc NYSE:PLTR	Technology
US	C	C3.ai Inc NYSE:AI	Technology
US		Uber Technologies Inc NYSE:UBER	Road & Rail
CN		NIO Inc NYSE:NIO	Automobiles
US		Fluor Corp NYSE:FLR	Construction
US		Jacobs Engineering Group Inc NYSE:J	Professional Services
US		TopBuild Corp NYSE:BLD	Consumer products
US		Abbott Laboratories NYSE:ABT	Health Care
US		Chevron Corp NYSE:CVX	Energy
US		Occidental Petroleum Corp NYSE:OXY	Energy
US		Matrix Service Co NASDAQ:MTRX	Construction
US		Automatic Data Processing Inc NASDAQ:ADP	Technology
US		Qualcomm Inc NASDAQ:QCOM	Semiconductors
US		Ambarella Inc NASDAQ:AMBA	Semiconductors

Add Price Alert

Price Target:

Last Price: 129.81 USD

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

ASND Alert

Ascendis Pharma A/S

129.81

+7.17 (+5.85%)

52 Week Range	90.62 159.4
Price Target

We'll email you a reminder when the closing price reaches USD.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Fubotv Inc NYSE:FUBO	US
	Bank of America Corp NYSE:BAC	US
	Palantir Technologies Inc NYSE:PLTR	US
C	C3.ai Inc NYSE:AI	US
	Uber Technologies Inc NYSE:UBER	US
	NIO Inc NYSE:NIO	CN
	Fluor Corp NYSE:FLR	US
	Jacobs Engineering Group Inc NYSE:J	US
	TopBuild Corp NYSE:BLD	US
	Abbott Laboratories NYSE:ABT	US
	Chevron Corp NYSE:CVX	US
	Occidental Petroleum Corp NYSE:OXY	US
	Matrix Service Co NASDAQ:MTRX	US
	Automatic Data Processing Inc NASDAQ:ADP	US
	Qualcomm Inc NASDAQ:QCOM	US
	Ambarella Inc NASDAQ:AMBA	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Ascendis Pharma A/S

What unique competitive advantages
does Ascendis Pharma A/S hold over its rivals?

What risks and challenges
does Ascendis Pharma A/S face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Ascendis Pharma A/S.

What unique competitive advantages
does Ascendis Pharma A/S hold over its rivals?

What risks and challenges
does Ascendis Pharma A/S face in the near future?

Summarize the latest earnings call
of Ascendis Pharma A/S.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ascendis Pharma A/S.

Provide P/S
for Ascendis Pharma A/S.

Provide P/E
for Ascendis Pharma A/S.

Provide P/OCF
for Ascendis Pharma A/S.

Provide P/FCFE
for Ascendis Pharma A/S.

Provide P/B
for Ascendis Pharma A/S.

Provide EV/S
for Ascendis Pharma A/S.

Provide EV/GP
for Ascendis Pharma A/S.

Provide EV/EBITDA
for Ascendis Pharma A/S.

Provide EV/EBIT
for Ascendis Pharma A/S.

Provide EV/OCF
for Ascendis Pharma A/S.

Provide EV/FCFF
for Ascendis Pharma A/S.

Provide EV/IC
for Ascendis Pharma A/S.

Show me price targets
for Ascendis Pharma A/S made by professional analysts.

What are the Revenue projections
for Ascendis Pharma A/S?

How accurate were the past Revenue estimates
for Ascendis Pharma A/S?

What are the Net Income projections
for Ascendis Pharma A/S?

How accurate were the past Net Income estimates
for Ascendis Pharma A/S?

What are the EPS projections
for Ascendis Pharma A/S?

How accurate were the past EPS estimates
for Ascendis Pharma A/S?

What are the EBIT projections
for Ascendis Pharma A/S?

How accurate were the past EBIT estimates
for Ascendis Pharma A/S?

Compare the revenue forecasts
for Ascendis Pharma A/S with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ascendis Pharma A/S and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ascendis Pharma A/S against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ascendis Pharma A/S compared to its peers.

Compare the P/E ratios
of Ascendis Pharma A/S against its peers.

Discuss the investment returns and shareholder value creation
comparing Ascendis Pharma A/S with its peers.

Analyze the financial leverage
of Ascendis Pharma A/S compared to its main competitors.

Show all profitability ratios
for Ascendis Pharma A/S.

Provide ROE
for Ascendis Pharma A/S.

Provide ROA
for Ascendis Pharma A/S.

Provide ROIC
for Ascendis Pharma A/S.

Provide ROCE
for Ascendis Pharma A/S.

Provide Gross Margin
for Ascendis Pharma A/S.

Provide Operating Margin
for Ascendis Pharma A/S.

Provide Net Margin
for Ascendis Pharma A/S.

Provide FCF Margin
for Ascendis Pharma A/S.

Show all solvency ratios
for Ascendis Pharma A/S.

Provide D/E Ratio
for Ascendis Pharma A/S.

Provide D/A Ratio
for Ascendis Pharma A/S.

Provide Interest Coverage Ratio
for Ascendis Pharma A/S.

Provide Altman Z-Score Ratio
for Ascendis Pharma A/S.

Provide Quick Ratio
for Ascendis Pharma A/S.

Provide Current Ratio
for Ascendis Pharma A/S.

Provide Cash Ratio
for Ascendis Pharma A/S.

What is the historical Revenue growth
over the last 5 years for Ascendis Pharma A/S?

What is the historical Net Income growth
over the last 5 years for Ascendis Pharma A/S?

What is the current Free Cash Flow
of Ascendis Pharma A/S?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ascendis Pharma A/S.

EV/EBITDA
Enterprise Value to EBITDA

-22.8

Current

-12.2

Median

4.2

Industry

Lower than median

Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA

-22.8

Enterprise Value

8B USD

EBITDA

-334.8m EUR

All Countries

Forward Multiples

			Market Cap	EV/EBITDA
DK		Ascendis Pharma A/S NASDAQ:ASND	7.6B USD	-22.8
FR		Pharnext SCA OTC:PNEXF	6T USD	-219 796.6
US		Abbvie Inc NYSE:ABBV	312.7B USD	15.3
US		Amgen Inc NASDAQ:AMGN	158.3B USD	17.5
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	115.9B USD	24
US		Gilead Sciences Inc NASDAQ:GILD	112.4B USD	9.9
US	E	Epizyme Inc F:EPE	94.1B EUR	-514.1
AU		CSL Ltd ASX:CSL	133.6B AUD	20.3
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	82.6B USD	16.2
US	S	Seagen Inc F:SGT	39.3B EUR	-58.7
NL		argenx SE XBRU:ARGX	34.5B EUR	-104.5

				EBITDA Growth
DK		Ascendis Pharma A/S NASDAQ:ASND	Average EV/EBITDA: 17.2 Negative Multiple: -22.8	N/A
FR		Pharnext SCA OTC:PNEXF	Negative Multiple: -219 796.6	N/A
US		Abbvie Inc NYSE:ABBV	15.3	29%
US		Amgen Inc NASDAQ:AMGN	17.5	62%
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	24	43%
US		Gilead Sciences Inc NASDAQ:GILD	9.9	16%
US	E	Epizyme Inc F:EPE	Negative Multiple: -514.1	N/A
AU		CSL Ltd ASX:CSL	20.3	42%
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	16.2	35%
US	S	Seagen Inc F:SGT	Negative Multiple: -58.7	N/A
NL		argenx SE XBRU:ARGX	Negative Multiple: -104.5	N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

EV/EBITDA

-21.8

2-Years Forward

EV/EBITDA

-50.6

3-Years Forward

EV/EBITDA

45.6

Ascendis Pharma A/S
NASDAQ:ASND

EV/EBITDA
Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

Ascendis Pharma A/S NASDAQ:ASND

EV/EBITDA Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

Ascendis Pharma A/S
NASDAQ:ASND

EV/EBITDA
Enterprise Value to EBITDA